US Pharma MarketingThe post Alpha Cognition begins enrolment in RESOLVE Phase IV trial for Zunveyl appeared first on Clinical Trials Arena.
Alpha Cognition begins enrolment in RESOLVE Phase IV trial for Zunveyl
Alpha Cognition has started enrolling patients in its RESOLVE Phase IV study, which is evaluating Zunveyl as a treatment for mild-to-moderate Alzheimer’s. The study aims to enrol about 150 patients across multiple sites. RESOLVE’s safety and effectiveness data will complement earlier evidence and inform Zunveyl use as a treatment for Alzheimer’s disease. Credit: digicomphoto / Shutterstock.com. Alpha Cognition has started enrolling patients in its RESOLVE Phase IV post-marketing study, which is evaluating the tolerability and real-world treatment experience of Zunveyl (benzgalantamine) in patients with mild-to-moderate Alzheimer’s disease. The multi-centre, post-approval trial will collect tolerability and safety data on Zunveyl, focusing…
Alpha Cognition has started enrolling patients in its RESOLVE Phase IV study, which is evaluating Zunveyl as a treatment for mild-to-moderate Alzheimer’s.
Source: Clinical Trials Arena